Professor of Medical Oncology at the University Paris VII (Denis Diderot), Clinical and Translational Research, at Hôpitaux Universitaires Saint-Louis Lariboisière Fernand Widal, Assistance Publique-Hôpitaux de Paris. She is MD & PhD, working on signaling involved in tumor proliferation, invasion, angiogenesis, and microenvironment to generate scientific rationale for innovative cancer targets. She has been investigator of more than 100 phase I/II studies, published first-in- man phase I trials of sunitinib, temsirolimus, everolimus, and investigates molecular biomarkers of sensitivity/resistance to targeted agents including immunotherapy. In addition to gastrointestinal oncology, head & neck oncology, she focuses on phase I/II trials including molecular pharmacology and translational research using VEGFR-multikinase inhibitors, FGFR inhibitors, TGFbeta and PD-1/PD-L1 inhibitors among others. She is a member of the ILCA, AACR, ASCO, ESMO. She has published more than 180 peer-reviewed papers.